Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00572637
Recruitment Status : Completed
First Posted : December 13, 2007
Last Update Posted : May 20, 2010
Information provided by:
Ethical Oncology Science

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : March 2010
  Study Completion Date : March 2010